Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 28
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 1351 | PUBLIC JOINT STOCK SIBUR HOLDING PJSC SIBUR HOLDING | 11 | 436.4% | 0 | 7 | 2022–2026 |
| 1352 | QUANTA ASSOCIATES L P | 11 | 00% | 0 | 11 | 2022–2024 |
| 1353 | RAFAEL ADVANCED DEFENSE SYSTEMS | 11 | 00% | 0 | 11 | 2023–2026 |
| 1354 | RICOH | 11 | 436.4% | 3 | 4 | 2022–2026 |
| 1355 | SAINT GOBAIN SULLY | 11 | 19.1% | 0 | 10 | 2022–2026 |
| 1356 | SANJET INTERNATIONAL | 11 | 19.1% | 0 | 10 | 2021–2025 |
| 1357 | SCHENCK PROCESS EUROPE | 11 | 436.4% | 0 | 7 | 2022–2024 |
| 1358 | SERVICENOW | 11 | 00% | 0 | 11 | 2025–2026 |
| 1359 | SOFTBANK | 11 | 00% | 0 | 11 | 2024–2026 |
| 1360 | SOURCE GLOBAL PBC | 11 | 327.3% | 0 | 8 | 2020–2023 |
| 1361 | SPARK THERAPEUTICS | 11 | 00% | 2 | 9 | 2022–2026 |
| 1362 | SPREADTRUM SEMICONDUCTOR NANJING | 11 | 19.1% | 1 | 9 | 2022–2026 |
| 1363 | SSI NEW MATERIAL ZHENJIANG | 11 | 00% | 0 | 11 | 2023–2026 |
| 1364 | ST UBLI SARGANS | 11 | 327.3% | 2 | 6 | 2020–2025 |
| 1365 | SUMITOMO SHI FW ENERGIA | 11 | 436.4% | 0 | 7 | 2022–2024 |
| 1366 | SYENSQO | 11 | 654.5% | 2 | 3 | 2022–2024 |
| 1367 | TAE TECHNOLOGIES | 11 | 00% | 1 | 10 | 2022–2024 |
| 1368 | TESSENDERLO GROUP | 11 | 19.1% | 0 | 10 | 2022–2025 |
| 1369 | THREE SMITH GROUP | 11 | 436.4% | 0 | 7 | 2022–2025 |
| 1370 | TOKAMAK ENERGY | 11 | 19.1% | 2 | 8 | 2021–2024 |
| 1371 | TRAILHEAD BIOSYSTEMS | 11 | 00% | 6 | 5 | 2023–2025 |
| 1372 | TRIPLE WIN TECHNOLOGY SHENZHEN | 11 | 00% | 0 | 11 | 2024–2025 |
| 1373 | UMICORE BATTERY MATERIALS FINLAND | 11 | 00% | 0 | 11 | 2025–2026 |
| 1374 | UTILITY GLOBAL | 11 | 00% | 0 | 11 | 2023–2026 |
| 1375 | VALE | 11 | 19.1% | 0 | 10 | 2022–2026 |
| 1376 | VICAT | 11 | 218.2% | 0 | 9 | 2022–2025 |
| 1377 | VIRENT | 11 | 00% | 0 | 11 | 2024–2026 |
| 1378 | VISTERRA | 11 | 00% | 0 | 11 | 2022–2025 |
| 1379 | VOICEAGE | 11 | 218.2% | 2 | 7 | 2021–2025 |
| 1380 | VULCANFORMS | 11 | 00% | 7 | 4 | 2022–2024 |
| 1381 | WIREPAS | 11 | 19.1% | 0 | 10 | 2022–2025 |
| 1382 | X DEVELOPMENT | 11 | 00% | 0 | 11 | 2024–2026 |
| 1383 | XRIS | 11 | 00% | 0 | 11 | 2022–2025 |
| 1384 | ZHEJIANG GEELY HOLDING GROUP | 11 | 00% | 0 | 11 | 2024–2026 |
| 1385 | 1FINITY | 10 | 330% | 0 | 7 | 2021–2026 |
| 1386 | ADARX PHARMACEUTICALS | 10 | 00% | 0 | 10 | 2023–2026 |
| 1387 | AKOUOS | 10 | 00% | 1 | 9 | 2022–2024 |
| 1388 | ALBIREO | 10 | 110% | 2 | 7 | 2022–2024 |
| 1389 | ARCUS BIOSCIENCES | 10 | 00% | 3 | 7 | 2022–2025 |
| 1390 | ARGENX | 10 | 00% | 1 | 9 | 2022–2025 |
| 1391 | ASTER | 10 | 220% | 0 | 8 | 2022–2026 |
| 1392 | ATLAS COPCO AIRPOWER | 10 | 00% | 0 | 10 | 2022–2024 |
| 1393 | AVANTAMA | 10 | 220% | 1 | 7 | 2022–2025 |
| 1394 | AVANTIUM KNOWLEDGE CENTRE | 10 | 220% | 2 | 6 | 2022–2024 |
| 1395 | BAUERFEIND | 10 | 220% | 0 | 8 | 2016–2025 |
| 1396 | BELDEN CANADA ULC | 10 | 00% | 0 | 10 | 2024–2026 |
| 1397 | BENDIX COMMERCIAL VEHICLE SYSTEMS | 10 | 00% | 0 | 10 | 2023–2025 |
| 1398 | BIOCYTOGEN PHARMACEUTICALS BEIJING | 10 | 00% | 1 | 9 | 2022–2026 |
| 1399 | BIOVERATIV THERAPEUTICS | 10 | 00% | 1 | 9 | 2022–2024 |
| 1400 | BIOVERSYS | 10 | 110% | 0 | 9 | 2022–2025 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →